logo

Radiomic Analysis and Data Insights for Enhancing Hepatocellular Carcinoma Immunotherapy Outcomes

Sector: Hospital • Location: Spain

Source: EU Funding & Tenders Portal

Project
Ongoing

Hepatocellular carcinoma (HCC) ranks the sixth most common cancer and third leading cause of cancer-related death worldwide. Most patients are diagnosed at an advanced stage. For advanced HCC immunotherapy has been approved as the standard-of-care first-line treatment. However, only about one third of patients respond to immunotherapy. How to predict immunotherapy efficacy and early identify HCC p

Project Information FAQ

Project Information

3 Q
The project “Radiomic Analysis and Data Insights for Enhancing Hepatocellular Carcinoma Immunotherapy Outcomes” is an infrastructure initiative in the Hospital sector, located in Spain. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ongoing

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

Hepatocellular carcinoma (HCC) ranks the sixth most common cancer and third leading cause of cancer-related death worldwide. Most patients are diagnosed at an advanced stage. For advanced HCC immunotherapy has been approved as the standard-of-care first-line treatment. However, only about one third of patients respond to immunotherapy. How to predict immunotherapy efficacy and early identify HCC patients who are likely to benefit from it is an urgent clinical problem. RADIANT-HOPE aims to address this problem by developing and externally validating a radiomics model based on clinical routine computed tomography (CT) images. To achieve this, a novel comprehensive framework will be proposed to automatically segment the tumor, expand the tumor margin, and extract radiomics features from intra- and peritumor regions at pretreatment triphasic CT images. These features will be unsupervised clustered into clinically meaningful sub-phenotypes, and patients are stratified into different risk groups of immunotherapy response. Multi-omic data (e.g. mRNA) will be profiled and compared between the sub-phenotypes. Radiogenomic analysis will be performed to evaluate their genomic foundation. The model will be validated in independent international cohorts and developed as software for facilitating clinical utility. This project adopts highly interdisciplinary and intersectoral approaches, integrating oncology, immunology, radiology, artificial intelligence, and bioinformatics. The proposed radiomics model has the potential to provide a non-invasive, accurate, wide accessible imaging biomarker for predicting immunotherapy efficacy and patient stratification. The model implementation in clinic will contribute to HCC personalized treatment, optimize healthcare resources allocation and significantly reduce healthcare costs. As a hepatobiliary surgeon and clinic-oriented researcher, my extensive experience in HCC and radiomics & AI makes me an ideal candidate to conduct this project.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data